Observational Study
Copyright ©The Author(s) 2025.
World J Gastrointest Surg. Aug 27, 2025; 17(8): 104568
Published online Aug 27, 2025. doi: 10.4240/wjgs.v17.i8.104568
Table 2 Treatment administration details
Treatment component
n (%)
TACE procedures3 (1-6)
Chemotherapeutic agents
Doxorubicin70 (93.3)
Cisplatin65 (86.7)
Embolic agents
Lipiodol72 (96)
Gelatin sponge particles60 (80)
Targeted therapy agents
Bevacizumab40 (53.3)
Cetuximab25 (33.3)
Panitumumab10 (13.3)